Startup profile · funding coverage
Santa Ana Bio funding, valuation and investors
Precision immunology biotech for autoimmune and inflammatory diseases.
Keep track of Santa Ana Bio
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$125M · June 2024
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$168M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Alameda, CA
Investors in latest funding
Other: Andreessen Horowitz
Overview
Santa Ana Bio is a precision immunology company developing targeted therapies for autoimmune and inflammatory diseases. The Alameda, California-based biotech emerged from stealth in June 2024 with $168M in combined Series A and B funding. The $43M Series A was led by founding investor Versant Ventures with TPG and GV; the $125M Series B was led by GV with new investors including Andreessen Horowitz Bio + Health, Access Biotechnology, and RTW. CEO Carolyn Baum, former Kite Pharma executive, leads a pipeline of three programs — a monoclonal antibody, bispecific, and antibody-drug conjugate — targeting clinic entry. Santa Ana's multi-omics platform uses transcriptomics and proteomics to expand precision medicine beyond current commercial biologics.
Why Santa Ana Bio is interesting
Ex-Kite Pharma leader at the helm with $168M launch — multi-omics platform targets cell types and pathways current biologics miss.
Product & use cases
Santa Ana Bio uses a multi-omics platform (transcriptomics and proteomics) to develop precision immunology therapeutics targeting cell types and pathways beyond current biologics.
- Precision antibody therapeutics for autoimmune diseases
- Bispecific and ADC programs for inflammatory conditions
- Multi-omics target discovery expanding precision medicine reach
Key facts
- Launch (Jun 2024): $168M combined Series A ($43M) and B ($125M)
- CEO Carolyn Baum, former Kite Pharma executive (FierceBiotech)
- Three programs (mAb, bispecific, ADC) targeting clinic entry
- a16z Bio + Health joined Series B alongside GV, Versant, RTW
Funding history (newest first)
Series B
2024-06 $125MSource: https://www.businesswire.com/news/home/20240613791090/en/Santa-Ana-Bio-Launches-With-168-Million/
Investors in our directory
Funds linked from Santa Ana Bio's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: $168M launch capital and ex-Kite Pharma leadership. Multi-omics platform addresses limitations of current commercial immunology biologics.
Autoimmune biologics is a $100B+ market dominated by Humira successors. Santa Ana's thesis is multi-omics can find targets current biologics miss. $168M provides runway into 2027 with two Phase I datasets planned. Clinical validation remains ahead.
-
AbbVie (Humira/Rinvoq) incumbent
Dominant immunology franchise; Santa Ana targets pathways current drugs miss.
-
Roivant Sciences adjacent
Immunology pipeline via subsidiary model; different structure.
-
Academic immunology labs adjacent
Basic research on autoimmune mechanisms; Santa Ana translates to clinic.
Notable stories
- Santa Ana Bio launched with $168M and an ex-Kite Pharma CEO, planning three antibody programs into clinic within a year of stealth exit (FierceBiotech, 2024).
Industries
Related funding articles
Venture Capital Tracker pieces that cover Santa Ana Bio's financing or category context.
FAQs about Santa Ana Bio
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.